DemeRx

DemeRx is a clinical-stage biopharmaceutical company based in Miami, Florida, dedicated to transforming the treatment of addiction. The company is developing DMX-1001, an oral formulation of noribogaine, as an investigational therapy for alcohol use disorder (AUD), a condition affecting over 29 million people in the United States. Noribogaine is the active metabolite of ibogaine, a naturally occurring psychoactive substance that has shown potential to induce neuroplasticity—the brain's ability to adapt and change—and thereby help reset dysregulated stress and reward pathways that underlie substance use disorders. The company was founded by Dr. Deborah Mash, PhD, who serves as Chief Executive Officer and President and is a board member. Dr. Mash's research on noribogaine as a neuroplastogen positioned DemeRx at the forefront of addiction therapeutics. The leadership team includes Mark Ellison, PhD, as President of Clinical Operations and Chief Development Officer; E. Douglas Kramer, MD, as Vice President of Clinical and Regulatory Affairs; John C. Thomas Jr. as Chief Financial Officer and Secretary; and Michael Snitkovsky as Chief Operating Officer. DemeRx's mission is to pioneer transformative neuroplastogen medications that empower individuals in recovery from addiction disorders. The company aims to revolutionize addiction treatment by leveraging the neuroplasticity induced by noribogaine to restore and reset the brain's addiction circuitry, facilitating faster and more effective treatment of substance use disorders. Its focus is on developing DMX-1001 for AUD, with the goal of providing new hope for those affected by alcohol and drug abuse and contributing to overall public health improvement. In recent news, DemeRx announced FDA acceptance of its Investigational New Drug (IND) application to advance DMX-1001 for the treatment of alcohol use disorder. The company also highlighted its participation in the Commissioner's National Priority Voucher (CNPV) Pilot Program. These developments underscore DemeRx's progress in clinical development and its commitment to addressing the unmet needs of patients with addiction.

DemeRx is a clinical-stage biopharmaceutical company based in Miami, Florida, focused on developing transformative treatments for addiction disorders. The company was founded by Dr. Deborah Mash, PhD, whose groundbreaking research on the neuroplastogen noribogaine—the active metabolite of ibogaine—laid the foundation for DemeRx's therapeutic approach. Dr. Mash serves as Chief Executive Officer and President and is a member of the board. Noribogaine is a naturally derived compound that has shown the ability to induce neuroplasticity, the brain's capacity to reorganize itself by forming new neural connections. Chronic misuse of alcohol and drugs disrupts brain wiring, creating a compulsive drive for substances despite harmful consequences. DemeRx aims to leverage noribogaine's neuroplastic effects to restore and reset the brain's addiction circuitry, potentially offering faster and more effective treatment for substance use disorders. The company's lead investigational product is DMX-1001, an oral formulation of noribogaine being developed for alcohol use disorder (AUD), which affects over 29 million people in the United States. DemeRx has progressed DMX-1001 through preclinical and clinical development, and has announced FDA acceptance of its Investigational New Drug (IND) application to advance the therapy for AUD. The company has also participated in the FDA's Commissioner's National Priority Voucher (CNPV) Pilot Program. DemeRx's leadership team brings together extensive experience in drug development, addiction treatment, pharmaceuticals, and neuroscience. Key executives include Mark Ellison, PhD, President of Clinical Operations and Chief Development Officer; E. Douglas Kramer, MD, Vice President of Clinical and Regulatory Affairs; John C. Thomas Jr., Chief Financial Officer and Secretary; and Michael Snitkovsky, Chief Operating Officer. Together, they are committed to delivering innovative therapies for patients suffering from addiction. As a private company, DemeRx continues to focus on advancing its pipeline and achieving regulatory milestones. Its mission is to revolutionize addiction therapeutics and provide new hope for individuals and families affected by alcohol and drug abuse.

• FDA accepts Investigational New Drug (IND) application for DMX-1001 for alcohol use disorder

• Participation in FDA Commissioner's National Priority Voucher (CNPV) Pilot Program

Clinical-stage biopharmaceutical company focused on developing neuroplastogen medications for addiction disorders, with a lead investigational therapy for alcohol use disorder.

• DMX-1001

  Oral noribogaine, an investigational neuroplastogen therapy for alcohol use disorder.

• 2020.01.24

  Reported2020.01.24

  ATAI Life Sciences announces joint ventures with DemeRx[4]ATAI Life Sciences宣布与DemeRx成立合资企业prnewswire.com

  ATAI Life Sciences announced an investment in two separate joint ventures with DemeRx to develop ibogaine and noribogaine for opioid use disorder.

Read more

1. 1DemeRx - Transforming Treatment for AUDdemerx.com
2. 2DemeRx - About Usdemerx.com
3. 3DemeRx (United States) - Wikidatawikidata.org
4. 4ATAI Life Sciences宣布与DemeRx成立合资企业prnewswire.com